BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 19, 2014
View Archived Issues
Results from phase I trial of PF-06438179, a biosimilar to infliximab
Read More
ABP-501 proves equivalent to adalimumab in healthy volunteers
Read More
NNC-0151-0000 development halted, second-generation compound shows improved profile
Read More
Selexipag meets endpoint in pivotal phase III study in PAH
Read More
Inovio Pharmaceuticals expands license agreement with the University of Pennsylvania
Read More
Phase III perampanel trial meets primary endpoint in primary generalized tonic-clonic seizures
Read More
Isis Pharmaceuticals earns milestone payment under Biogen Idec collaboration
Read More
PsiOxus initiates phase I/II study of enadenotucirev for ovarian cancer
Read More
GW Pharmaceuticals reports expanded-access data for Epidiolex
Read More
Eculizumab receives U.S. orphan drug designation for myasthenia gravis
Read More
FDA award orphan drug designation to COTI-2 for ovarian cancer
Read More
Senhwa Biosciences begins phase I/II trial of CX-4945
Read More
Galapagos provides progress update on R&D programs
Read More
Bioequivalence of LY-2963016 to originator insulin glargine
Read More
GlaxoSmithKline presents new IFN-alpha inducers
Read More
GlaxoSmithKline describe novel DGAT1 inhibitors
Read More
Novel phosphodiesterase PDE10A inhibitors synthesized at Merck & Co.
Read More
Piramal Enterprises patents new proinflammatory cytokine inhibitors
Read More
Enrollment complete in phase IIa trial of GALE-301 immunotherapy in gynecological cancer
Read More
New IDO inhibitors prepared by Vertex Pharmaceuticals
Read More
Immunomodulator HMPL-523 enters first-in-human trial
Read More
Selecta Biosciences outlines pipeline progress and reveals new product candidate
Read More
Endocyte regains rights to vintafolide
Read More
Allergan acknowledges second unsolicited exchange offer from Valeant
Read More
BMS-817399 fails to improve rheumatoid arthritis in phase II proof-of-concept study
Read More
Takeda terminates development of orteronel for prostate cancer
Read More
Boehringer Ingelheim and Lilly resubmit empagliflozin NDA
Read More